�㽶��Ƶ News - Alzheimer’s

KalGene gears up to manufacture and test promising Alzheimer’s treatment with NRC, McGill and CIMTEC

webfull — Mon, 03 Oct 2016 18:55:49 +0000

KalGene Pharmaceuticals and the National Research Council of Canada (NRC) are proud to announce the signature of an agreement worth over $1M to develop, scale up, and transfer the technology needed to manufacture a promising novel Alzheimer’s treatment in Canada that the parties have been co- developing since 2015.

The treatment, a biologic molecule made up of a peptide that fights Alzheimer’s and an antibody-based carrier molecule designed to shuttle the peptide into the brain, is a custom- engineered therapeutic developed at NRC.

Published: 3 October 2016

“Big Data” study discovers earliest sign of Alzheimer’s development

webfull — Mon, 11 Jul 2016 14:09:46 +0000

Research underlines importance of computational power in future neurological breakthrough

Scientists at the Montreal Neurological Institute and Hospital have used a powerful tool to better understand the progression of late-onset Alzheimer’s disease (LOAD), identifying its first physiological signs.

Published: 11 July 2016

Everything in moderation: excessive nerve cell pruning leads to disease

webfull — Tue, 08 Oct 2013 13:59:41 +0000

Mechanism meant to maintain efficiency of brain network involved in neurodegenerative disease

Published: 8 October 2013